Skip to main content
Premium Trial:

Request an Annual Quote

David Voris, Michael Venuti, Peter Staple

Premium
Cyntellect has appointed David Voris as its vice president of finance and administration and CFO, the company said this week. Voris' appointment was effective Nov. 5.
 
Voris most recently served as the CFO of SynergEyes. Previously he had served as CFO of Laser Diagnostic Technologies from 1999 until its sale to Carl Zeiss Meditec in 2004.
 
Voris has also held various positions in finance and operations with companies including Alaris Medical Systems and Metracor Technologies. He began his career as a CPA at Deloitte & Touche.
 

 
BioSeek last week appointed Michael Venuti as CEO and board member. Venuti succeeds Peter Staple, who will continue his involvement with BioSeek as an investor and board member.
 
Venuti previously served as CEO of Discovery Partners International, a small
molecule-based drug discovery services company.
 
Prior to joining Discovery Partners, he served as general manager of Celera Genomics Group's South San Francisco site after its acquisition of Axys Pharmaceuticals. He also served as senior vice president of research andpreclinical development of Axys Pharmaceuticals prior to its acquisition by Celera.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.